F19.27 Other psychoactive substance dependence with psychoactive substance-induced persisting dementia

Name of the Condition

• Other Psychoactive Substance Dependence with Psychoactive Substance-Induced Persisting Dementia
• ICD-10 Code: F19.27

Summary

This condition involves a pattern of dependence on non-classified psychoactive substances (excluding alcohol, opioids, or cannabis) that leads to clinically significant impairment, alongside persistent dementia caused by the substance's effects. The dependence is marked by a strong desire to use the substance, difficulty controlling use, and continued use despite negative consequences, while the dementia persists beyond the acute effects of the substance.

Causes

The condition stems from chronic use of psychoactive substances that alter brain function, leading to both dependence and irreversible cognitive changes. Psychological factors like stress or trauma, combined with social influences such as peer pressure, may contribute to prolonged substance use. The dementia arises from direct neurotoxic effects of the substance on the brain, resulting in lasting cognitive decline.

Risk Factors

• Genetic predisposition to addiction
• Co-occurring mental health disorders (e.g., anxiety, depression)
• Early exposure to psychoactive substances
• Environmental access to substances or social norms supporting use

Symptoms

• Intense cravings or urges to use the substance
• Inability to reduce or control use despite efforts
• Persistent cognitive decline (e.g., memory loss, impaired judgment)
• Withdrawal symptoms when not using (e.g., irritability, fatigue)
• Neglect of personal, occupational, or social responsibilities

Diagnosis

Diagnosis requires a thorough medical and psychological evaluation, including patient self-reports of substance use patterns and standardized assessments for cognitive impairment. Laboratory tests may rule out other causes of dementia, and imaging studies (e.g., MRI) can identify structural brain changes. The diagnosis confirms both dependence and substance-induced persisting dementia.

Treatment Options

Treatment typically involves a combination of substance use disorder interventions (e.g., counseling, medication-assisted therapy) and cognitive rehabilitation. Supportive care focuses on managing withdrawal symptoms and addressing cognitive deficits. Long-term monitoring is essential to prevent relapse and address ongoing dementia-related challenges.

Prognosis and Follow-Up

Prognosis depends on the severity of dependence and the extent of cognitive damage. Early intervention may improve outcomes, but persistent dementia often requires ongoing support. Regular follow-up with healthcare providers, including cognitive assessments and substance use monitoring, is critical to manage symptoms and prevent complications.

Complications

• Worsening cognitive decline
• Increased risk of accidents or injuries due to impaired judgment
• Social isolation or relationship difficulties
• Higher likelihood of relapse or co-occurring mental health issues

Lifestyle & Prevention

• Avoiding use of non-classified psychoactive substances
• Seeking early treatment for substance use concerns
• Engaging in cognitive-stimulating activities to support brain health
• Building a strong support network to reduce relapse risk

When to Seek Professional Help

Seek immediate medical attention if experiencing severe withdrawal symptoms, sudden cognitive changes, or inability to manage daily tasks. Consult a healthcare provider for persistent substance cravings or signs of dementia, such as memory loss or confusion.

Tips for Medical Coders

Document the presence of both substance dependence and substance-induced persisting dementia clearly in the medical record. Ensure the diagnosis aligns with clinical criteria for both conditions, including evidence of cognitive impairment persisting beyond the acute effects of the substance. Code F19.27 is appropriate when both dependence and dementia are documented and linked to the same psychoactive substance use.